503B distinction and prioritize 503B outsourcing facilities for injectable GLP-1 medications whenever possible
**Blood Sugar Regulation**: Semaglutide enhances insulin secretion and inhibits glucagon release, helping to control blood sugar levels
Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK
Irritation : Topical glutathione products can sometimes cause skin irritation, redness, or itching
The delayed gastric emptying caused by GLP-1 medications can affect the absorption of oral medications, particularly those requiring rapid absorption or those with narrow therapeutic windows
For context on the full medication landscape, Meto's semaglutide medication page and Wegovy page provide current clinical information relevant to patients navigating their options